Matthew Gline - Roivant Sciences CEO Director
| ROIV Stock | USD 11.64 0.17 1.44% |
Insider
Matthew Gline is CEO Director of Roivant Sciences
| Age | 40 |
| Address | 50 Broadway, London, United Kingdom, SW1H 0DB |
| Phone | 44 20 7400 3347 |
| Web | https://roivant.com |
Matthew Gline Latest Insider Activity
Tracking and analyzing the buying and selling activities of Matthew Gline against Roivant Sciences stock is an integral part of due diligence when investing in Roivant Sciences. Matthew Gline insider activity provides valuable insight into whether Roivant Sciences is net buyers or sellers over its current business cycle. Note, Roivant Sciences insiders must abide by specific rules, including filing SEC forms every time they buy or sell Roivant Sciences'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Matthew Gline over three weeks ago Disposition of 10945 shares by Matthew Gline of Roivant Sciences at 11.92 subject to Rule 16b-3 | ||
Matthew Gline over two months ago Disposition of 10947 shares by Matthew Gline of Roivant Sciences at 11.48 subject to Rule 16b-3 | ||
Matthew Gline over six months ago Disposition of 994373 shares by Matthew Gline of Roivant Sciences subject to Rule 16b-3 | ||
Matthew Gline over six months ago Disposition of 10945 shares by Matthew Gline of Roivant Sciences at 10.01 subject to Rule 16b-3 |
Roivant Sciences Management Efficiency
The company has return on total asset (ROA) of (0.1503) % which means that it has lost $0.1503 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 1.2771 %, meaning that it created $1.2771 on every $100 dollars invested by stockholders. Roivant Sciences' management efficiency ratios could be used to measure how well Roivant Sciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to climb to 0.64 in 2024. Return On Capital Employed is likely to climb to 0.64 in 2024. At this time, Roivant Sciences' Total Assets are fairly stable compared to the past year. Net Tangible Assets is likely to climb to about 1.6 B in 2024, whereas Non Currrent Assets Other are likely to drop slightly above 32.7 M in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| Richard Heyman | Syndax Pharmaceuticals | 67 | |
| William JD | Akero Therapeutics | 51 | |
| Federico MD | Apellis Pharmaceuticals | 50 | |
| Joseph JD | Phathom Pharmaceuticals | N/A | |
| ric MD | Pliant Therapeutics | 60 | |
| Donald MBA | Lyra Therapeutics | 70 | |
| Andreas Orth | Krystal Biotech | 54 | |
| Demetrios MD | Inozyme Pharma | N/A | |
| David Pompliano | Revolution Medicines | N/A | |
| Katherine Tuminello | Krystal Biotech | N/A | |
| Steve Andre | Cullinan Oncology LLC | N/A | |
| Charles II | Day One Biopharmaceuticals | 47 | |
| Bill DeGrado | Pliant Therapeutics | N/A | |
| MA MS | Inozyme Pharma | N/A | |
| Michael Downes | Syndax Pharmaceuticals | N/A | |
| Aditya Kohli | Phathom Pharmaceuticals | 36 | |
| Jenna Cohen | Blueprint Medicines Corp | N/A | |
| Cedric MD | Apellis Pharmaceuticals | 52 | |
| Jacquelyn JD | Cullinan Oncology LLC | 46 | |
| Michael MBA | Syndax Pharmaceuticals | 53 | |
| Nur Nicholson | Apellis Pharmaceuticals | 54 | |
Management Performance
| Return On Equity | 1.28 | ||||
| Return On Asset | -0.15 |
Roivant Sciences Leadership Team
Elected by the shareholders, the Roivant Sciences' board of directors comprises two types of representatives: Roivant Sciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Roivant. The board's role is to monitor Roivant Sciences' management team and ensure that shareholders' interests are well served. Roivant Sciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Roivant Sciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Amy Mahery, Chief Officer | ||
| Matthew Gline, CEO Director | ||
| Marianne Romeo, Head Management | ||
| Huafeng Xu, Chief Officer | ||
| Josh Chen, General Counsel | ||
| Matt Maisak, Chief Platforms | ||
| Vivek Ramaswamy, Founder Chairman | ||
| Alex Gasner, Executive Health | ||
| Jo Chen, General Counsel | ||
| PharmD MD, President COO | ||
| Drew Kramer, Chief Officer | ||
| Kelly Graff, Head People | ||
| Richard Pulik, Chief Officer | ||
| Deya MD, Chief OfficerInResidence | ||
| Srini Ramanathan, Chief Officer | ||
| Rakhi Kumar, Chief Officer | ||
| Mayukh MD, Chief President | ||
| David MD, Chief Dermavant |
Roivant Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Roivant Sciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 1.28 | ||||
| Return On Asset | -0.15 | ||||
| Profit Margin | 29.92 % | ||||
| Operating Margin | (4.02) % | ||||
| Current Valuation | 3.31 B | ||||
| Shares Outstanding | 739.52 M | ||||
| Shares Owned By Insiders | 29.09 % | ||||
| Shares Owned By Institutions | 79.11 % | ||||
| Number Of Shares Shorted | 46.57 M | ||||
| Price To Book | 1.58 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Roivant Stock Analysis
When running Roivant Sciences' price analysis, check to measure Roivant Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Roivant Sciences is operating at the current time. Most of Roivant Sciences' value examination focuses on studying past and present price action to predict the probability of Roivant Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Roivant Sciences' price. Additionally, you may evaluate how the addition of Roivant Sciences to your portfolios can decrease your overall portfolio volatility.